Alexion’s researchers were the first to discover that a group of proteins called inhibiting terminal complement has therapeutic potentials. Inhibiting terminal complement has an important role in the human body’s immune system.
As a result of its extensive researches, Alexion was able to develop the drug Soliris® (Eculizumab). Soliris is the first in its class of terminal complement inhibitor and is used today in over 40 countries to treat patients with PNH (paroxysmal nocturnal hemoglobinuria). In the US and Europe, Soliris® is used to treat patients with aHUS (atypical hemolytic uremic syndrome).
Alexion continues with its research efforts to further investigate Soliris® and find out its indication for other severe and rare diseases.